Bed Bath & Beyond Inc. just released its third-quarter fiscal 2017 financial results, posting earnings of 44 cents per share and revenues of $3 billion.
Currently, BBBY is a Zacks Rank #4 (Sell) and is down 2.32% to $24.00 per share in after-hours trading shortly after its earnings report was released.
Bed Bath & Beyond:
Beat earnings estimates. The company posted earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.36.
Beat revenue estimates. The company saw revenue figures of $3.0 billion, topping our consensus estimate $2.90 billion.
Total revenues were relatively flat year-over-year. Comparable-store sales increased about 0.3%. Comps from customer-facing digital channels “continued to have strong growth,” while comps from stores “decline in the low-single-digit percentage range.”
The company declared a quarterly dividend of $.15 per share, to be paid on April 17 to shareholders of record at the close of business on March 16. Management also said that its full-year earnings guidance of $3.00 per share has not changed.
Here’s a graph that looks at Bed Bath & Beyond’s earnings surprise history:
Bed Bath & Beyond Inc. is a retailer offering a wide selection of domestics merchandise and home furnishings. The company operates a robust ecommerce platform consisting of various websites and applications. The company also operates an established retail store base under the names of Bed Bath & Beyond, Christmas Tree Shops, Harmon, Harmon Face Values or Face Values, buybuy BABY, World Market, Cost Plus World Market or Cost Plus.
Check back later for our full analysis on BBBY’s earnings report!
Want more stock market analysis from this author? Make sure to follow @Ryan_McQueeney on Twitter!
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Image: Bigstock
Bed Bath & Beyond (BBBY) Posts Earnings and Revenue Beats
Bed Bath & Beyond Inc. just released its third-quarter fiscal 2017 financial results, posting earnings of 44 cents per share and revenues of $3 billion.
Currently, BBBY is a Zacks Rank #4 (Sell) and is down 2.32% to $24.00 per share in after-hours trading shortly after its earnings report was released.
Bed Bath & Beyond:
Beat earnings estimates. The company posted earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.36.
Beat revenue estimates. The company saw revenue figures of $3.0 billion, topping our consensus estimate $2.90 billion.
Total revenues were relatively flat year-over-year. Comparable-store sales increased about 0.3%. Comps from customer-facing digital channels “continued to have strong growth,” while comps from stores “decline in the low-single-digit percentage range.”
The company declared a quarterly dividend of $.15 per share, to be paid on April 17 to shareholders of record at the close of business on March 16. Management also said that its full-year earnings guidance of $3.00 per share has not changed.
Here’s a graph that looks at Bed Bath & Beyond’s earnings surprise history:
Bed Bath & Beyond Inc. Price, Consensus and EPS Surprise
Bed Bath & Beyond Inc. Price, Consensus and EPS Surprise | Bed Bath & Beyond Inc. Quote
Bed Bath & Beyond Inc. is a retailer offering a wide selection of domestics merchandise and home furnishings. The company operates a robust ecommerce platform consisting of various websites and applications. The company also operates an established retail store base under the names of Bed Bath & Beyond, Christmas Tree Shops, Harmon, Harmon Face Values or Face Values, buybuy BABY, World Market, Cost Plus World Market or Cost Plus.
Check back later for our full analysis on BBBY’s earnings report!
Want more stock market analysis from this author? Make sure to follow @Ryan_McQueeney on Twitter!
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>